DBV Technologies SA (DBVT)
9.11
+0.24
(+2.71%)
USD |
NASDAQ |
Oct 15, 16:00
8.86
-0.25
(-2.74%)
After-Hours: 05:13
DBV Technologies Research and Development Expense (Quarterly) : 28.96M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.96M |
| March 31, 2026 | 31.31M |
| December 31, 2025 | 30.04M |
| September 30, 2025 | 26.82M |
| June 30, 2025 | 32.23M |
| March 31, 2025 | 18.59M |
| December 31, 2024 | 18.77M |
| September 30, 2024 | 22.24M |
| June 30, 2024 | 23.64M |
| March 31, 2024 | 19.07M |
| December 31, 2023 | 28.03M |
| Date | Value |
|---|---|
| September 30, 2023 | 15.94M |
| June 30, 2023 | 15.44M |
| March 31, 2023 | 14.48M |
| December 31, 2022 | 23.07M |
| September 30, 2022 | 14.32M |
| June 30, 2022 | 17.44M |
| March 31, 2022 | 10.42M |
| December 31, 2021 | 11.64M |
| September 30, 2021 | 16.32M |
| June 30, 2021 | 20.18M |
| March 31, 2021 | 22.16M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Cellectis SA | 20.89M |
| Akari Therapeutics Plc | 2.081M |
| EDAP TMS SA | 2.314M |
| Bicycle Therapeutics Plc | 47.76M |
| Autolus Therapeutics Plc | 27.95M |